CABS Webinar: Leverage Global Clinical Resources for Drug Development

Date: September 25, 2020 @ 2:00 pm – @ 4:00 pm
Location: Zoom Conference

CABS Webinar

Leverage Global Clinical Resources for Drug Development

US Pacific Time: September 25 (Friday), 2020, 2:00pm-4:00pm

How to Perform Early Stage Trials in US

China Drug Regulatory Reform and Include China in Next Trial

Manage Global Clinical Trials During COVID-19 Pandemic

Webinar is Free and No Registration Required

Join Webinar through Zoom:

Add to Outlook Calendar

Add to Google Calendar

(Wechat user, please click upper right corner and choose "open in Safari", then you can add to calendar with one click)


(This event will be broadcast to you through Zoom Conference; agenda is based on US Pacific Time)

2:00pm - 2:05pm Introduction to CABS, Dr. Yang Tian, President of CABS

2:05pm - 2:40pm Phase I Clinical Trials in the USA – Maximizing Value, Managing Risk. Lisa E. Diamond, PhD, President, Frontage Clinical Services.

2:40pm - 3:15pm Including China into Your Drug Development Strategy: Why, When, and How. Jiansong Yang, PhD, CSO and SVP, Tigermed

3:15pm - 3:50pm China’s significant role in the handling of COVID-19 global pandemic. Melika Davis, MS, VP, and Le Dao, BS, PMP, Associate Director, BeiGene

3:50pm - 4:10pm Panel Discussion


Lisa E. Diamond, PhD, President, Frontage Clinical Services

As President of Frontage Clinical Services since 2018, Dr. Diamond provides oversight for Clinical Study Conduct and Analyses, Client Relations, and Business Development activities.

Dr. Diamond joined Frontage as Director of Clinical Affairs in 2005, was Vice-President of Clinical Affairs and Project Management in 2009-2013, and rejoined Frontage in 2017 as Vice-President of Clinical Affairs, US and China. In these positions she managed cross-functional teams, including Data Management, Programming, Biostatistics, Project Management and Medical Writing, provided Clinical Operations oversight and supported Business Development and Client Relations. Her prior positions in academia, small biopharmaceutical companies, Palatin Technologies, DNX and Nextran (1989-2005) and at Bristol-Myers Squibb (2013-2017), contribute to a broad experience base in research and development, preclinical and clinical research, a detailed knowledge of GCP/ICH guidelines, and a solid background in oncology, immunology, diabetes, autoimmune disease and transplantation research.

Dr. Diamond earned her Doctor of Philosophy and Master of Science degrees in Basic Medical Sciences from New York University (New York, Ny), and her Bachelor of Science degree from Suffolk University (Boston, MA). She completed her post-doctoral training at Princeton University (Princeton, NJ), and is an adjunct professor at Rider University (Lawrenceville, NJ).

Jiansong Yang, PhD, CSO&SVP, Tigermed

Dr. Jiansong Yang is the Chief Scientific Officer of Tigermed, which is the largest clinical CRO in China. He’s also the Founder and CEO of Mosim (now a Tigermed company), where he leads a team of over 100 scientists focusing on drug development strategy, clinical study design and PK/PD data analysis.

Dr Yang has over 15 years of experience in the pharmaceutical industry, specialized in early drug development and clinical study design. Prior to Mosim, he was Director of Clinical Pharmacology at GSK. He received his Ph.D. on Clinical Pharmacokinetics from the University of Sheffield, UK.

Melika Davis, MS, Vice President,BeiGene

Melika is the VP of Global Clinical Operations at BeiGene and leads a team of about 400 associates around the world, responsible for the planning and execution of all Clinical Trials’ activities.

Melika has 15 years of senior management experience and 25 years of Clinical Research and Development Quality Assurance experience.  Through designing and building successful global organizations, Melika and her teams have brought, on the worldwide market, 20+ products in the last 10 years, mainly in Oncology, Vaccines, and Anti-Infectives. Melika has led teams up to 700+ associates in Clinical Monitoring Operations and managed a portfolio up to 1,500 clinical trials a year.

Prior to joining BeiGene, Melika held numerous positions at Novartis and Schering Plough Research Institute of increasing responsibilities across the Research and the Development organizations in the areas of Oncology, Transplant, Anti-Infective, Respiratory, and Vaccines.

Melika holds a Master’s degree in Molecular Biology from Texas Women’s University in Dallas, Texas and a License de Physiologie from the University of Sciences in Nice, France.

Le Dao, BS, PMP, Associate Director, BeiGene

Le is an Associate Director of Portfolio and Program Management at BeiGene and is responsible for management of clinical programs in early stage development. She has 20+ years of clinical development experience and PM expertise that includes team management, business insights, clinical pharmacology (PK/PD) and combination product development across multiple disease areas, including oncology/CIT, immunology, and infectious disease. She has a strong record of collaboration across multidisciplinary functions in building and delivering on strategic plans. In addition to her technical industry expertise, she is passionate about making a meaningful difference in patients’ lives, community building, and leadership development.

Le holds a Bachelor’s degree in Chemistry from University of California, Los Angeles.

Webinar is Free and No Registration Required

Join Webinar through Zoom:

Add to Outlook Calendar

Add to Google Calendar

(Wechat user, please click upper right corner and choose "open in Safari", then you can add to calendar with one click)